头颈部肿瘤碳离子放疗后咽鼓管功能障碍所致分泌性中耳炎的剂量学分析
本研究回顾性分析2013年10月至2018年12月在本机构接受碳离子放疗且咽鼓管受照的141例头颈部肿瘤患者,中位随访25.2个月,65例发生2-3级分泌性中耳炎,中位发生时间6.5个月;多因素分析显示软骨部分平均剂量是独立预测因素,软骨部分平均剂量<40.59 Gy(相对生物效应)与≥40.59 Gy(相对生物效应)患者的2年发生率分别为24.2%(95%CI 15.1%-37.4%)和66.4%(95%CI 54.5%-78.0%)。
要点
- 141例头颈部肿瘤碳离子放疗患者中,65例发生2-3级分泌性中耳炎,中位发生时间6.5个月。
- 软骨部分平均剂量是2-3级分泌性中耳炎的独立预测因素。
- 软骨部分平均剂量<40.59 Gy(相对生物效应)者2年发生率为24.2%,≥40.59 Gy(相对生物效应)者为66.4%。
核心结论
- 本研究发现可能有助于在碳离子放疗前预测咽鼓管功能障碍所致2-3级分泌性中耳炎的风险。
研究设计与样本
- 回顾性分析2013年10月至2018年12月在本机构接受碳离子放疗且咽鼓管受照的141例头颈部肿瘤患者。
- 采用log-rank检验和Cox比例风险模型分析影响2-3级分泌性中耳炎发生的临床因素和剂量学参数。
主要发现
- 中位随访25.2个月,65例发生2-3级分泌性中耳炎,中位发生时间6.5个月。
- 多因素分析显示软骨部分平均剂量是2-3级分泌性中耳炎的显著独立预测参数。
- 软骨部分平均剂量<40.59 Gy(相对生物效应)患者2年发生率为24.2%(95%CI 15.1%-37.4%),≥40.59 Gy(相对生物效应)患者为66.4%(95%CI 54.5%-78.0%)。
关键数值与推荐
- 分泌性中耳炎严重程度按乳突气房浑浊体积比例分级:0级<5%,1级6%-33%,2级34%-67%,3级68%-100%。
- 软骨部分平均剂量<40.59 Gy(相对生物效应)者2年2-3级分泌性中耳炎发生率为24.2%(95%CI 15.1%-37.4%)。
- 软骨部分平均剂量≥40.59 Gy(相对生物效应)者2年2-3级分泌性中耳炎发生率为66.4%(95%CI 54.5%-78.0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to clarify the predictive factors for otitis media with effusion (OME) due to Eustachian tube dysfunction in patients treated with carbon-ion radiation therapy (CIRT) for head and neck cancers. METHODS AND MATERIALS: We investigated patients with head and neck cancer whose Eustachian tube was irradiated by CIRT between October 2013 and December 2018 at our institution. OME severity was assessed by the proportion of mastoid cell opacification of magnetic resonance or computed tomography imaging (grade 0: <5% of volume of mastoid cell with opacification by fluid collection; grade 1: 6%-33%; grade 2: 34%-67%; and grade 3: 68%-100%). Clinical factors and dosimetric parameters affecting the development of grade 2 to 3 OME were analyzed using a log-rank test and Cox proportional hazards model. RESULTS: In total, 141 patients were analyzed. The median follow-up period was 25.2 months. Grade 2 to 3 OME was observed in 65 patients, with a median incidence period of 6.5 months. According to the multivariate analysis, the mean dose of the cartilage part was a significant independent predictive parameter of grade 2 to 3 OME. The 2-year incidence rate of patients with a mean dose of the cartilage part of <40.59 Gy (relative biological effectiveness) and ≥40.59 Gy (relative biological effectiveness) was 24.2% (95% confidence interval, 15.1%-37.4%) and 66.4% (95% confidence interval, 54.5%-78.0%), respectively. CONCLUSIONS: Our findings may be useful to predict the risk of grade 2 to 3 OME due to Eustachian tube dysfunction before CIRT.
引用
- Kaneko T, Koto M, Ikawa H, et al. Dosimetric Analysis for Otitis Media With Effusion Due to Eustachian Tube Dysfunction After Carbon-ion Radiation Therapy for Head and Neck Cancers. Adv Radiat Oncol. 2022. PMID: 36483056. doi:10.1016/j.adro.2022.101115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。